Rapid and Long-term Response of Pulmonary Pleomorphic Carcinoma to Nivolumab

Pulmonary pleomorphic carcinoma (PPC) is a rare very aggressive subtype of non-small cell lung cancer. We herein report a case of PPC that showed a rapid response to nivolumab. The patient, whose multiple tumors had progressed very aggressively, was treated with nivolumab, an anti-programmed cell de...

Descripción completa

Detalles Bibliográficos
Autores principales: Senoo, Satoru, Ninomiya, Takashi, Makimoto, Go, Nishii, Kazuya, Kano, Hirohisa, Watanabe, Hiromi, Hata, Yusuke, Kubo, Toshio, Tanaka, Takehiro, Hotta, Katsuyuki, Maeda, Yoshinobu, Kiura, Katsuyuki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Japanese Society of Internal Medicine 2018
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6478974/
https://www.ncbi.nlm.nih.gov/pubmed/30568113
http://dx.doi.org/10.2169/internalmedicine.0890-18
Descripción
Sumario:Pulmonary pleomorphic carcinoma (PPC) is a rare very aggressive subtype of non-small cell lung cancer. We herein report a case of PPC that showed a rapid response to nivolumab. The patient, whose multiple tumors had progressed very aggressively, was treated with nivolumab, an anti-programmed cell death-1 (PD-1) antibody. The tumors dramatically shrank after one cycle of nivolumab. The tumors were positive for programmed cell death ligand 1 (PD-L1). An immunohistochemical analysis revealed numerous PD-1(+), CD68(+) and CD206(+) macrophages. This PD-1 antibody may be a good treatment option, especially in tumors that express PD-L1 and which show PD-1(+) macrophage infiltration.

Ejemplares similares